Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,totalCashFromFinancingActivities,issuanceOfStock,totalCashflowsFromInvestingActivities,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,priceHint,shortName,longName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchange,market,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,exchangeDataDelayedBy,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Oct 14, 2018) 4","Short Ratio (Oct 14, 2018) 4","Short % of Float (Oct 14, 2018) 4","Short % of Shares Outstanding (Oct 14, 2018) 4","Shares Short (prior month Sep 13, 2018) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,IMUC,3427448.0,4193500,58981,,-306704,,-306704,670203,0,-729184,-729184,,,,,,0,0,729184,0,422480,,-306704,-306704,121198601.0,401944.0,3427448.0,3829392.0,4191.0,489657.0,-117775344.0,2852605.0,401944.0,356.0,3829036.0,486774.0,84256.0,-1040621.0,-889402.0,-2173997.0,-2173997.0,106.0,62624.0,,,,,3427092.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.0,0.3801 - 0.46,0.3801,0.0,0.0,9,30,finmb_27792717,Other OTC,USD,6640,5728,0.3211,5.442373,0.059 - 0.98,-0.5999,-0.61214286,0.059,0.98,1600214400,1489093200,1503604800,1503691200,-2.69,-0.64,-14400000,0.817,0.48697144,-0.106871426,-0.21946138,0.5764275,-0.19632751,4,IMMUNOCELLULAR THERAPEUTICS LTD,"ImmunoCellular Therapeutics, Ltd.",0.3801,1630525792,0.0,0.4,0.46,0.3801,3021,PRE,PNK,us_market,-0.34059358,1593949,-0.5939063,0.46523872,15,America/New_York,EDT,False,False,0,1.39,,,0.98,0.059,0.487,0.5764,6.64k,5.73k,4.19M,,4.18M,0.00%,0.00%,165.95k,4.13,3.96%,3.96%,147.78k,,,,,,0.00%,"Sep 15, 2020",,1:10,"Sep 15, 2020","Dec 30, 2017","Jun 29, 2018",0.00%,0.00%,-88.07%,"-2,312.00%",,,,,-6.07M,-9.03M,-2.6900,,2.85M,0.68,,,9.53,0.82,-10.93M,-9.22M,Value,91362,Healthcare,3,"ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers. The company is developing Steam-to-T-Cell immunotherapies for the treatment of cancer. It has license agreements with California Institute of Technology and The Johns Hopkins University. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California.",Westlake Village,818-264-2300,CA,1514678400,United States,http://www.imuc.com,86400,30721 Russell Ranch Road,818-224-5287,Biotechnology,Suite 140
t-1,IMUC,3671528.0,4193500,290616,,-1024981,,-1024981,734581,0,-1025197,-1025197,,,,,,0,0,1025197,0,216,,-1024981,-1024981,121135977.0,1493161.0,3671528.0,5164689.0,4191.0,137625.0,-117468640.0,5026602.0,1493161.0,462.0,5164227.0,,1124877.0,-649749.0,23318.0,-1603268.0,-1603268.0,106.0,48038.0,,,,,3671066.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.0,0.3801 - 0.46,0.3801,0.0,0.0,9,30,finmb_27792717,Other OTC,USD,6640,5728,0.3211,5.442373,0.059 - 0.98,-0.5999,-0.61214286,0.059,0.98,1600214400,1489093200,1503604800,1503691200,-2.69,-0.64,-14400000,0.817,0.48697144,-0.106871426,-0.21946138,0.5764275,-0.19632751,4,IMMUNOCELLULAR THERAPEUTICS LTD,"ImmunoCellular Therapeutics, Ltd.",0.3801,1630525792,0.0,0.4,0.46,0.3801,3021,PRE,PNK,us_market,-0.34059358,1593949,-0.5939063,0.46523872,15,America/New_York,EDT,False,False,0,1.39,,,0.98,0.059,0.487,0.5764,6.64k,5.73k,4.19M,,4.18M,0.00%,0.00%,165.95k,4.13,3.96%,3.96%,147.78k,,,,,,0.00%,"Sep 15, 2020",,1:10,"Sep 15, 2020","Dec 30, 2017","Jun 29, 2018",0.00%,0.00%,-88.07%,"-2,312.00%",,,,,-6.07M,-9.03M,-2.6900,,2.85M,0.68,,,9.53,0.82,-10.93M,-9.22M,Value,91362,Healthcare,3,"ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers. The company is developing Steam-to-T-Cell immunotherapies for the treatment of cancer. It has license agreements with California Institute of Technology and The Johns Hopkins University. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California.",Westlake Village,818-264-2300,CA,1514678400,United States,http://www.imuc.com,86400,30721 Russell Ranch Road,818-224-5287,Biotechnology,Suite 140
t-2,IMUC,4648471.0,4193500,-676736,,-431295,,-431295,1108427,0,-431691,-431691,,,,,,0,0,431691,0,396,,-431295,-1622630,121087939.0,2360754.0,4648471.0,7009225.0,4191.0,378787.0,-116443659.0,6629870.0,2360754.0,568.0,7008657.0,,1774626.0,-1932555.0,-2615288.0,624572.0,-4928874.0,637.0,49627.0,5553446.0,5625945.0,,,4647903.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.0,0.3801 - 0.46,0.3801,0.0,0.0,9,30,finmb_27792717,Other OTC,USD,6640,5728,0.3211,5.442373,0.059 - 0.98,-0.5999,-0.61214286,0.059,0.98,1600214400,1489093200,1503604800,1503691200,-2.69,-0.64,-14400000,0.817,0.48697144,-0.106871426,-0.21946138,0.5764275,-0.19632751,4,IMMUNOCELLULAR THERAPEUTICS LTD,"ImmunoCellular Therapeutics, Ltd.",0.3801,1630525792,0.0,0.4,0.46,0.3801,3021,PRE,PNK,us_market,-0.34059358,1593949,-0.5939063,0.46523872,15,America/New_York,EDT,False,False,0,1.39,,,0.98,0.059,0.487,0.5764,6.64k,5.73k,4.19M,,4.18M,0.00%,0.00%,165.95k,4.13,3.96%,3.96%,147.78k,,,,,,0.00%,"Sep 15, 2020",,1:10,"Sep 15, 2020","Dec 30, 2017","Jun 29, 2018",0.00%,0.00%,-88.07%,"-2,312.00%",,,,,-6.07M,-9.03M,-2.6900,,2.85M,0.68,,,9.53,0.82,-10.93M,-9.22M,Value,91362,Healthcare,3,"ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers. The company is developing Steam-to-T-Cell immunotherapies for the treatment of cancer. It has license agreements with California Institute of Technology and The Johns Hopkins University. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California.",Westlake Village,818-264-2300,CA,1514678400,United States,http://www.imuc.com,86400,30721 Russell Ranch Road,818-224-5287,Biotechnology,Suite 140
t-3,IMUC,-523307.0,4193500,2763659,,-3900879,,-3900879,1137329,0,-3900988,-3900988,,,,,,0,0,3900988,0,109,,-3900879,-6079190,115486679.0,7299068.0,-523307.0,6775761.0,2378.0,710803.0,-116012364.0,6005298.0,7299068.0,59660.0,6716101.0,,3765636.0,-420464.0,1967314.0,4191293.0,-2219719.0,13941.0,666067.0,6409686.0,2148180.0,1326.0,140929.0,-582967.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.0,0.3801 - 0.46,0.3801,0.0,0.0,9,30,finmb_27792717,Other OTC,USD,6640,5728,0.3211,5.442373,0.059 - 0.98,-0.5999,-0.61214286,0.059,0.98,1600214400,1489093200,1503604800,1503691200,-2.69,-0.64,-14400000,0.817,0.48697144,-0.106871426,-0.21946138,0.5764275,-0.19632751,4,IMMUNOCELLULAR THERAPEUTICS LTD,"ImmunoCellular Therapeutics, Ltd.",0.3801,1630525792,0.0,0.4,0.46,0.3801,3021,PRE,PNK,us_market,-0.34059358,1593949,-0.5939063,0.46523872,15,America/New_York,EDT,False,False,0,1.39,,,0.98,0.059,0.487,0.5764,6.64k,5.73k,4.19M,,4.18M,0.00%,0.00%,165.95k,4.13,3.96%,3.96%,147.78k,,,,,,0.00%,"Sep 15, 2020",,1:10,"Sep 15, 2020","Dec 30, 2017","Jun 29, 2018",0.00%,0.00%,-88.07%,"-2,312.00%",,,,,-6.07M,-9.03M,-2.6900,,2.85M,0.68,,,9.53,0.82,-10.93M,-9.22M,Value,91362,Healthcare,3,"ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers. The company is developing Steam-to-T-Cell immunotherapies for the treatment of cancer. It has license agreements with California Institute of Technology and The Johns Hopkins University. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California.",Westlake Village,818-264-2300,CA,1514678400,United States,http://www.imuc.com,86400,30721 Russell Ranch Road,818-224-5287,Biotechnology,Suite 140
